HomeNewsGlobal Pharma

Cognizant Extends Alliance with Gilead to Boost Advanced Technology Applications

Cognizant Extends Alliance with Gilead to Boost Advanced Technology Applications

Cognizant has extended its longstanding relationship with Gilead Sciences that aims to unlock even greater value for Gilead as it advances innovations to prevent and treat life-threatening diseases.

The expanded agreement aims to deliver greater cost leadership and productivity enhancement for Gilead while seeking to extract greater value from the existing relationship. Leveraging machine learning and generative AI within an agentic framework, the work addresses multiple use cases across customer service, employee interactions, and business value management.

Gilead is expected to enhance its efficiency through leveraging Cognizant's expertise in AI and advanced technology applications. By deploying these cutting-edge solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.

Over the last decade, Cognizant has helped support Gilead's global IT infrastructure, platforms, applications and advanced analytics, and leads initiatives designed to accelerate its digital transformation. Today's announcement builds on a collaboration aimed at creating capacity to allow Gilead to continue its focus and mission, aimed at discovering and delivering critical medicines for cancer, HIV and other diseases. 

"Cognizant continues to provide critical expertise as we advance our technology journey. The expansion of this partnership is pivotal in accelerating our capabilities roadmap while driving a new level of cost leadership across our technology programs. This collaboration aims to bring innovative changes to Gilead's business, exploring new possibilities and enhancing our operations in novel ways," said Joydeep Ganguly, SVP & Head – Corporate Operations and Interim CIO at Gilead.

Expanding on the company's partnership, Cognizant intends to leverage its Neuro AI generative AI platform to assist Gilead in accelerating value creation, enhancing IT and business processes, and improving operational efficiencies. This initiative aims to provide significant cost savings, which can be reinvested into Gilead's core life sciences business.

As part of this expanded agreement, Cognizant also intends to transform the user experience of IT services with custom-built Gen AI solutions that allow Gilead to benefit from greater efficiency and user experience.

"We're proud of our longstanding relationship with Gilead, a leader in leveraging advanced technologies, and are excited about expanding our partnership in a new dimension with the company to deliver transformative treatments globally. Our teams will work together to transform user engagement, and boost productivity and cost savings for Gilead to focus on the critical work they do around preventing and treating life-threatening illnesses," said Surya Gummadi, EVP and President, Cognizant Americas.

"This agreement allows us to provide end-to-end Cognizant capabilities through our life sciences domain expertise to provide value acceleration to Gilead. Utilizing Cognizant's premier managed services frameworks and tools we intend to enhance operational efficiencies with leading-edge automation," said Mohammad Haque, SVP, Global Large Deals Lead and Business Unit Head, Life Sciences, Cognizant. 

More news about: global pharma | Published by Aishwarya | February - 03 - 2025

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members